Communiqué from the Extraordinary General Meeting in BiBBInstruments AB held on 13 March 2026

BiBB Instruments held an extraordinary general meeting on March 13, 2026 and approved amendments to the Articles of Association to change limits on share capital and the number of shares; the Board presented three alternative amendment proposals (Alternative A, Alternative B and a third option). The resolutions were adopted by the required majority; no financial details or dilution metrics were disclosed, so the announcement is unlikely to materially affect valuation absent further specifics.

Analysis

The corporate flexibility recently granted is a high-probability precursor to equity-related activity within a 3–6 month window — the most common playbook for small-cap medtechs is a rights issue or directed placement to fund clinical / commercial scale-up. Expect a near-term liquidity shock: similar Nordic small-cap rights issues compress free float and trade with immediate drawdowns of 15–35% intraday on execution, with a further 10–20% haircut by the offer close if discounting is steep.

Second-order winners are providers of short-term financing and placement desks (investment banks) who capture mandate fees and syndication spreads; losers are existing retail holders and option writers who suffer realized dilution. If management favors issuance over debt, suppliers with milestone-linked payment structures can see stretched payment timing 3–9 months out as cash goes into priority R&D spend, raising working-capital risk for OEM/service partners.

Tail risks include a large, opportunistic placement to a strategic investor that trades at a material control discount (>30%) — that would permanently reset float and governance (change-of-control clauses, lock-ups). Conversely, if proceeds are explicitly tied to a near-term clinical readout or commercialization milestone (6–12 months), the market could re-rate quickly and recoup >50% of the initial dilution within 9–18 months; monitor tranche timing and lock-up lengths closely for the inflection.

Key Decisions for Investors

• Short BIBB.ST into execution window (initiate 1–3% notional): target 20–35% downside over 1–3 months if a discounted placement/rights priced; use cash-secured short or borrow if available, stop-loss at 10% adverse move. Rationale: anticipate typical small-cap rights discounting and forced selling by anchor buyers.
• Buy 3–6 month puts on BIBB.ST (or equivalent OTC put structure) sized to cover short gamma — cost <5% of position value gives asymmetric downside protection if dilution >20%; ideal slippage-controlled hedge for existing long exposure.
• Event-driven long (speculative): accumulate post-raise after lock-up expiry or tranche completion (12–18% allocation scale-in over 3 tranches) — target >2x upside if proceeds are deployed to a clearly defined clinical / commercial milestone. Risk: dilution already priced; require explicit use-of-proceeds and milestone timetable before adding.
• If direct trading is constrained, implement a market-neutral pair: short BIBB.ST vs long a diversified Nordic medtech large-cap (e.g., GETI-B.ST) sized to be delta-neutral — horizon 3–9 months to capture relative underperformance during the issuance/overhang period.